Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Leukocyte-lymphatic intersections during cardiac inflammation

Glinton K., Thakkar AV., Jones R., Inui H., Ge ZD., Thorp EB.

Narrative Review on Cardiovascular Disease, published in J Mol Cell Cardiol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Mol Cell Cardiol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
39592090
PMCID
PMC11717605
DOI
10.1016/j.yjmcc.2024.11.006
Citations
1

Abstract (original English)

Advances in genetic, pharmacologic, and sequencing technology have led to new insight into the role of lymphatics in health and disease. This includes fundamental aspects of the crosstalk between immune cells with cardiac lymphatics. At the interface between leukocytes and lymphatic endothelial cells, myeloid populations are sources of lymphatic growth factors during inflammation. Lymphatic endothelial cells also secrete signals that activate leukocytes, including to antigen presenting cells. Taken together, a view of the lymphatic vasculature as a supplemental cardiac immune hub is emerging. Herein, we discuss reciprocal cell and molecular crosstalk between leukocytes and lymphatics in the myocardium, with implications for health and cardiac inflammation.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
MyocardiumLeukocytesEndothelial CellsLymphatic VesselsAnimalsHumansMyocarditis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research